By Frank Prenesti
Date: Monday 01 Oct 2018
(Sharecast News) - AstraZeneca said it had agreed a $200m deal with Germany's Cheplapharm Arzneimittel for the European commercial rights to Atacand and Atacand Plus heart and hypertension treatments.
| Sunday share tips: AstraZeneca, Genus, 'Dogs of ... | 30-Jul-2017 | ShareCast | 
| AstraZeneca co-develops treatment for Alzheimer'... | 09-Dec-2016 | ShareCast | 
No recent information was found.
| Questor :AstraZeneca | 29-Apr-2014 | Telegraph | 
| Questor : AstraZeneca | 24-Jan-2014 | Telegraph | 
| Questor:AstraZeneca | 22-Dec-2011 | Telegraph | 
| Investment Column:AstraZeneca | 28-Oct-2011 | The Independent | 
| Investment Column: AstraZeneca | 23-Jun-2011 | The Independent | 
| Currency | UK Pounds | 
| Share Price | 12,377.00p | 
| Change Today | -0.84p | 
| % Change | -0.67 % | 
| 52 Week High | 12,880.00p | 
| 52 Week Low | 9,642.00p | 
| Volume | 157,298 | 
| Shares Issued | 1,264.16m | 
| Market Cap | £156,465m | 
| Strong Buy | 10 | 
| Buy | 13 | 
| Neutral | 3 | 
| Sell | 0 | 
| Strong Sell | 1 | 
| Total | 27 | 

| Time | Volume / Share Price | 
| 16:29 | 5 @ 12,378.00p | 
| 16:29 | 82 @ 12,378.00p | 
| 16:29 | 140 @ 12,378.00p | 
| 16:29 | 19 @ 12,378.00p | 
| 16:29 | 30 @ 12,378.00p | 
You are here: research